Statera Biopharma Inc. (STAB)
0.00
-0.00 (-100.00%)
At close: Mar 13, 2025, 10:16 AM
Statera Biopharma Income Statement
| Year | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 | FY06 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 8.79B | 14.35M | n/a | n/a | 2.02M | 1.71M |
| Cost of Revenue | 488.31K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit | -488.31K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 8.79B | 14.35M | n/a | n/a | 2.02M | 1.71M |
| Operating Income | -98.34M | -10.5M | -2.81M | -4.8M | -5.6M | -6.36M | -10.79M | -14.42B | -23.08B | -30.05B | -25.11B | -12.83M | -6.38B | -14.35B | -27M | -7.22M |
| Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 183.66M | n/a | 21.69M | 259.84M | n/a | n/a |
| Pretax Income | -101.88M | -12.09M | -3.22M | -3.61M | -9.71M | -2.66M | -12.64M | 1.63B | -17.26B | -18.23B | -4.01B | -12.83M | -12.83B | -14.03B | -27M | -7.22M |
| Net Income | -174.41M | -13.22M | -3.35M | -3.61M | -9.71M | -2.66M | -12.64M | 1.63B | -17.26B | -18.23B | -4.01B | -12.83M | -12.83B | -14.03B | -27M | -7.22M |
| Selling & General & Admin | 18.49M | 5.24M | 2.23M | 2.32M | 2.5M | 3.38M | 6.36M | 8.47B | 12.04B | 11.12B | 11.11B | n/a | 6.4B | 5.89B | n/a | n/a |
| Research & Development | 11.83M | 5.26M | 587K | 3.62M | 5.05M | 6.5M | 7.14M | 9.65B | 19.53B | 22.5B | 22.79B | n/a | 14.33B | 13.16B | n/a | n/a |
| Other Expenses | -1.49M | -461.5K | -285.61K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -27.17M | n/a | n/a | 27.96M | 9.13M |
| Operating Expenses | 28.83M | 10.5M | 2.81M | 5.94M | 7.55M | 9.87M | 13.5M | 18.12B | 31.56B | 33.62B | 33.9B | -27.17M | 20.73B | 19.05B | 27.96M | 9.13M |
| Interest Expense | n/a | 1.13M | 124.23K | n/a | n/a | 263.65K | -99.49K | -1.09B | 83.13M | -70.02M | n/a | n/a | 1.96M | n/a | -1M | -195.46K |
| Selling & Marketing Expenses | 79.44K | 2.41K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 29.32M | 10.5M | 2.81M | 5.94M | 7.55M | 9.87M | 13.5M | 18.12B | 31.56B | 33.62B | 33.9B | -27.17M | 20.73B | 19.05B | 27.96M | 9.13M |
| Income Tax | 72.53M | 1.13M | 124.23K | -161.14K | -52.52K | -22.82K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Shares Outstanding (Basic) | 35.11M | 25.65M | 25.65M | 11.29M | 11.19M | 10.99M | 7.06M | 2.7B | 45B | 37.39B | 32.56B | n/a | n/a | n/a | n/a | n/a |
| Shares Outstanding (Diluted) | 35.11M | 25.65M | 25.65M | 11.29M | 11.19M | 10.99M | 7.06M | 2.7B | 45B | 37.39B | 32.56B | n/a | n/a | n/a | n/a | n/a |
| EPS (Basic) | -4.97 | -0.52 | -0.13 | -0.32 | -0.87 | -0.24 | -1.79 | 0.60 | -0.38 | -0.49 | -0.12 | -0.82 | 16.41M | 13.49M | n/a | n/a |
| EPS (Diluted) | -4.97 | -0.52 | -0.13 | -0.32 | -0.87 | -0.24 | -1.79 | 0.60 | -0.38 | -0.49 | -0.12 | -0.82 | 16.41M | 13.49M | n/a | n/a |
| EBITDA | 38.93M | -2.59M | -2.36M | -4.8M | -5.6M | -6.36M | -10.79M | -14.42B | -23.08B | -30.05B | -25.11B | -12.83M | -6.38B | -14.35B | -27M | -7.22M |
| Depreciation & Amortization | 255.57K | 947.00 | 13.78K | 18.18K | 21.08K | 63.46K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |